Market revenue in 2019 | USD 189.5 million |
Market revenue in 2027 | USD 416.5 million |
Growth rate | 10.3% (CAGR from 2019 to 2027) |
Largest segment | Humira |
Fastest growing segment | Others Drugs |
Historical data | 2016 - 2018 |
Base year | 2019 |
Forecast period | 2020 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs |
Key market players worldwide | AbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.
Humira was the largest segment with a revenue share of 24.49% in 2019. Horizon Databook has segmented the Japan ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2016 to 2027.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan ankylosing spondylitis market, including forecasts for subscribers. This country databook contains high-level insights into Japan ankylosing spondylitis market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account